Modulating NRF2 in Disease: Timing Is Everything
- PMID: 30256716
- PMCID: PMC6538038
- DOI: 10.1146/annurev-pharmtox-010818-021856
Modulating NRF2 in Disease: Timing Is Everything
Abstract
The transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.
Keywords: KEAP1; NRF2; cancer; clinical trials; disease; therapeutics.
Figures




References
-
- Wattenberg LW. 1978. Inhibitors of chemical carcinogenesis. Adv Cancer Res 26:197–226 - PubMed
-
- Benson AM, Batzinger RP, Ou SY, Bueding E, Cha YN, Talalay P. 1978. Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo(a)pyrene by dietary antioxidants. Cancer Res 38:4486–95 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources